Aignostics secures 34 million US dollars in Series B

Aignostics strengthens precision medicine through AI-based pathology models. Funds will be used for new products, US expansion and collaboration with Mayo Clinic

Berlin and NEW YORK, NY, October 29, 2024 - Aignostics, a global AI company analyzing multimodality pathology data, today announced $34 million in Series B funding. The additional funding will be used to develop new products for biopharmaceutical customers, expand in the US, and develop leading pathology foundation models in collaboration with the Mayo Clinic. The oversubscribed financing round was led by ATHOS, supplemented by investment from Mayo Clinic and growth funding from HTGF. Backers include existing investors such as Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund and VC Fonds Technologie managed by IBB Ventures. In total, Aignostics has now raised more than 55 million US dollars - a clear signal of investor confidence in its differentiated AI models and clear growth strategy.

Rethinking precision medicine: AI in biopharmaceutical research

With advances in precision medicine, particularly for diagnostics and drug development, the need for AI solutions to improve and scale pathology analysis is increasing. AI-based models are achieving ever greater accuracy and stability, opening up new opportunities for biopharmaceutical research and diagnostics.

This rapidly evolving field requires uncompromising scientific quality and constant innovation - Aignostics delivers exactly that, offering its customers transparency and scientific excellence at the highest level.

Julian Zachmann from ATHOS

Expansion into the USA and development of new products

The financing round will strengthen Aignostics in several strategic initiatives:

• "Plug-and-Play" products for pathology: a scalable product portfolio for various indications such as tumor microenvironments and biomarker profiling.
• US expansion: New employees and support for US partners to strengthen market presence.
• Foundation models with Mayo Clinic: Collaboration to develop pathology foundation models and offerings for the biopharma industry.

We are very impressed by Aignostics' progress and innovative AI platform. The transformative impact on R&D in the pharmaceutical industry is enormous and we look forward to continuing to support the team on this exciting journey.

Niels Sharman, Senior Investment Manager at HTGF

Viktor Matyas, CEO and co-founder of Aignostics, says: "2024 was a pivotal year for us with the cooperation with Bayer and the launch of our first foundation model RudolfV. Through RudolfV, we are able to develop cost-efficient algorithms for real-world use cases. With the new funding, we will turn popular algorithms into products that will usher in an era of generalizable AI in pathology."

Aignostics is an AI company that transforms multimodal pathology data into groundbreaking insights for precision medicine. The startup, which emerged from Charité Berlin in 2018, supports biopharma partners in drug development, translational research, clinical trials and CDx development. With offices in Berlin and New York and leading investors at its side, Aignostics is on its way to setting global standards in computer-assisted pathology.